Penpulimab (Anniko)

Mechanism of action

PD-1 inhibitor

Diseases for which it is used

• Classical Hodgkin lymphoma
• Non-small cell lung cancer, squamous

History of changes in NMPA indication

• 2021-08-05: Initial approval for treatment of patients with relapsed or refractory ("r/r") classic Hodgkin’s lymphoma ("cHL") after at least second-line systemic chemotherapy treatment.
• 2023-01-15: Approved in combination with chemotherapy as the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer (sq-NSCLC). (Based on AK105-302)

Also known as

• Code name: AK-105
• Generic name: pianprizumab
• Brand name: Anniko, Annikol